

2019 / 2020 ANNUAL REPORT



For forty years the Children's Leukaemia & Cancer Research Foundation (Inc.) has been raising funds for research into childhood cancers.

The Foundation relies on the generous support of the community to continue its vital research, as we do not receive State or Federal funding.



CONTENTS

04

FOUNDATION HISTORY

Childhood cancer is the single greatest cause of death from disease in Australian children, with three children losing their lives to cancer every week.

05

COMMITTEE OF MANAGEMENT

Meet our Committee of Management Team who are the driving force behind the directions we take.

06

CHAIRMAN'S REPORT

Our Chairman Geoff Cattach, AM cover grants, funding, finance and activities during the past financial year.

12

CEO'S REPORT

Our CEO Andrea Alexander reports on the financial year that was, covering Benefactors, Donations, Events, Activities and Communication for 2019/2020.

28

CLCRF LAB REPORT

Scientific reports direct from our CLCRF Funded Scientists in the Telethon Kids Institute Laboratory.

42

FINANCIAL MEMBERS

Meet our Financial Members for 2019/2020, who make a great contribution to our Foundation.

44

FINANCIAL STATEMENTS

We report on the 2019/2020 financial year.

Foundation History

Australia has one of the highest incidences of childhood cancer worldwide. One in 500 Australian children will develop a cancer before 15 years of age – that's 600 Australian children diagnosed every year.



This year is the Foundation's 40th year of raising funds and awareness for childhood cancer research.

The creation of the Foundation was inspired by nine-year-old Jennifer Harper, who was diagnosed with leukaemia in 1977. When her father, Peter Harper, discovered that there was no research into childhood cancer being done in Western Australia, he set out to raise funds with the help of other parents of children with cancer.

A fundraising committee was then formed in 1980 at Princess Margaret Children's Medical Research Foundation's (PMCMRF) comprised of Mr Peter Harper, Associate Professor Keven Turner, Mr AJ (John) Myers, Mr Peter Falconer, Mr Geoff Cattach, Mr Lou Giglia and Mr M Livesey.

During the 40 years since then, the fundraising committee became known as the Children's Leukaemia & Cancer Research Foundation (Inc.) and has raised a substantial amount of funds for important research projects that have assisted children in WA, nationwide, and internationally.

We are so proud of the ground-breaking work we have helped fund over the years and have been thrilled to see survival rates increase as a result. It was recorded that only 20 per cent of children with cancer survived 50 years ago, which has since improved to 80 per cent for some forms of cancer.

There is still however a lot more work to be done. Australia has one of the highest rates of childhood cancer in the world, with an average of 750 children under the age of 15 diagnosed each year. Data from the Australian Childhood Cancer Registry also suggests that childhood cancer rates in Australia are expected to increase by 7 per cent in the next 20 years.

The Foundation is committed to ensuring the research can continue for many more years, so that we can stop this rise and ensure less children and families have to go through the trauma that comes with a cancer diagnosis.

As the Foundation does not receive State or Federal funding, we rely on the generous support of people like you to continue funding this ground-breaking research. Please consider making a donation today or signing up to become a member.



Committee of Management

As at 30/06/20



Mr Geoffrey CATTACH, AM
(Chairman)



Mr Philip BRUCE
(Vice Chairman)



Mr Kim WILLIAMSON
(Treasurer)



Mr Justin BRUCE
(Secretary)



Mr Kimon ANDERSON



Professor Ursula KEES



Mr Michael PARKER

Life Members

Mr Philip BRUCE
Mr Geoffrey CATTACH, AM
Mr Peter FALCONER, OAM
Mr Peter HARPER
Professor Ursula KEES
Mr Kim WILLIAMSON

Founder

Mr Peter HARPER

Administration Staff

Mrs Andrea ALEXANDER
Chief Executive Officer



Mrs Kylie DALTON
Head of Development



Mrs Wendy KEARNS
Executive Officer



Ms Sophie GALATI
Communications Coordinator



Miss Katelyn LUSH
Executive Assistant
(Resigned in February 2020)



Chairman's Report

It is with pleasure that I once again report to members on the operations of the Children's Leukaemia & Cancer Research Foundation (Inc) for the year ended 30th June 2020.

Finance

2020 was a challenging year for the Foundation, meeting the challenges of COVID19, along with the downturn in the economy. Although, due to the Foundation's accumulated fund position, we have been able to meet all research funding requirements.

For the year under review, there was a deficit of \$636,946, compared to the surplus of \$774,87 in 2018/2019 period.

We expect the downturn to continue for at least the next 12 to 18 months. To ensure the Foundation's continued ability to support our childhood cancer research projects, we are investigating several growth strategies to future proof the funding capabilities.



Funding of Grants

I am pleased to report that for the period under review, our Foundation has been able to maintain the high level of research funding during 2019/20. A snapshot of the research grants currently being funded are as follows:

- | | |
|----|--|
| 01 | <p>Triennial Block Grant (2019 - 2021) Total Expenditure: \$817,365</p> <p>Researchers: Dr Rishi S Kotecha and Dr Laurence C Cheung</p> <p>Title: <i>Identifying Novel Translatable Therapeutics for Infant Acute Lymphoblastic Leukaemia</i></p> <p>Title: <i>Novel Therapeutics for Children with Leukaemia: Understanding and Targeting the Bone Marrow Microenvironment.</i></p> |
| 02 | <p>CLCRF Ursula Kees Fellow Total Expenditure: \$294,446</p> <p>Researcher: Dr Sebastian Malinge</p> <p>Title: <i>To develop new tools to identify cancer cells resistant to current therapy and test a new drug therapy to destroy them.</i></p> |
| 03 | <p>Creation of Appt of Program Manager for the Telethon Kids Cancer Centre Total Expenditure: \$28,998</p> <p>This position was created to work closely with the Head of the Telethon Kids Cancer Centre (TKCC). It will manage and support the TKCC's large, multidisciplinary research team working on a diverse portfolio of paediatric cancer research. This position commenced in early 2020. Funding is for five years.</p> <p><i>Total expenditure was \$1,140,809. Unexpended funds from the 2018/2019 were carried forward to cover this difference with the \$1M Partner payment to Telethon.</i></p> |
| 04 | <p>Telethon Grants Partnership – Oncogenic Signalling Laboratory Total Expenditure: \$194,822</p> <p>Researcher: Professor Terrance Johns</p> <p>Title: <i>Development of a new and effective therapy against Diffuse Intrinsic Pontine Glioma</i></p> |
| 05 | <p>Sarcoma Program – Co-funded by CLCRF and The Abbie Basson Sarcoma Foundation Total Expenditure: \$156,276</p> <p>Researcher: Dr Joost Lesterhuis</p> <p>Title: <i>A new treatment to prevent sarcoma relapse after surgery</i></p> |

NB: Research projects (four and five) have been supported by the additional funding of \$250K from Telethon (enabled by CLCRF's \$1M partnership) directly to the Telethon Kids Institute.

We are incredibly grateful and accordingly would like to congratulate Professor Terrance Johns, and our dedicated team of researchers for their continued achievements both locally and internationally.



Telethon Trust

Our agreement with the Telethon Trust to be a Million Dollar Partner commenced in 2017 and concluded in 2019.

Because of the three \$1M contributions made, an additional \$1.250M was donated from Telethon to the research projects being funded by CLCRF.

We believe this was an excellent co-funding relationship that provided benefit to all involved. Due to the ambiguity of COVID19, the Foundation has paused its funding arrangement in 2020. There is a possibility for further review in 2021.

Telethon Kids Institute

Once again, we are proud to acknowledge the wonderfully cooperative working relationship we enjoy with the Telethon Kids Institute and, in particular, extend our thanks and appreciation to Professor Jonathan Carapetis AM, the Institute's Director, and Ms Julie Bishop, the Institute's Chairwoman.



Marketing Strategy & Development

Absolute Edge Media (AEM) continue to create, manage and coordinate all of the Foundation's printed collateral. AEM maintain and create new website opportunities, and we will continue to enjoy this very supportive relationship provided by their team.



Community Activities

We continue to be amazed at the wonderful and varied support we receive from benefactors, businesses and the community at large.

Whilst such contributions will be individually acknowledged in our CEO's report, I would pay particular mention of the wonderful contribution of the Annual South West Bike Trek, which continues to attract support from many riders and various Lions and Rotary Clubs. Since its inception in 2002, this event has now raised approximately **\$766,504**.

Acknowledging the recent success of the South West Bike Trek over the past 18 years, I would like to specifically thank and congratulate Eric Maddock and his wife, Annette. Their tremendous effort and dedication have been the reason for these events continued success over the past four years.

I congratulate members of our Community Fundraising Committee, under the chairmanship of Justin Bruce and our own Foundation staff, combined with the dedicated volunteers who assisted in our fundraising efforts. I would like to acknowledge it is not just monies that are raised from these events, but the awareness created initiating even more generous support of our research endeavours.



Patron



Right: Justin Langer, AM - CLCRF Patron

We are delighted that Justin Langer, our inaugural Patron, has agreed to continue in this role for the next appointment period of 2021.

We were extremely privileged to have Justin accept the position as our first Patron – this will be his 20th year. Notwithstanding his many commitments, he has always given his support to the Foundation whenever called upon.

Committee of Management

It is with deep sadness that we accepted resignations from Kim Williamson (Foundation Treasurer) and Kimon Anderson from the Committee of Management in September this year.

Kim has been involved with the Foundation since November 1983, when he accepted the role of Secretary to the Committee. From April 1995 to June 1996 held the position of the Executive Officer. It was wonderful to serve with someone who has such knowledge, skills and whom we trusted implicitly. Kim showed an unwavering dedication to CLCRF, and we were very sorry to see him go.



Kimon has been on the Committee of Management since November 2013. We thank Kimon for his time on the committee and for the expertise he provided.

From everyone at the Foundation, we wish Kim and Kimon all the best to them and their families for their future endeavours.



To those remaining members of our Committee of Management, I personally thank you. All give willingly of their time and expertise, and business acumen, ensuring that our Foundation operates efficiently and effectively in their stewardship of our operations.

I am personally forever grateful to each and every member of the Committee of Management, they certainly make my role as Chairman a pleasure.

Foundation Staff

In January 2020, we had two new staff members join the CLCRF family - Kylie Dalton as Head of Development and Sophie Galati as Communications Co-ordinator. A warm welcome to them both.

Kylie and Sophie join our existing team of Andrea as CEO and Wendy as EO. We farewelled Katelyn, who left in February to join the Royal Australian Navy.

This year has been a difficult one with restrictions and the cancellation of events. Our staff were able to work remotely for a period of time, and the office continued to function efficiently. I would like to extend my personal appreciation to all staff for their commitment towards the Foundation during those challenging times.



Ambassadors

We are pleased to note that Georgia Lowry and radio personality, Lisa Fernandez are continuing in their roles of Ambassadors to the Foundation.

Our CLCRF Ambassadors, who, together with our Patron, Justin Langer, help provide a public and community awareness of the Foundation.

We are excited that all the Ambassadors will continue to support the Foundation in any way they can, showcasing the need for continued funding into childhood cancer research.



Conclusion

Our Foundation has been serving this community for 40 years. During this period, we have raised more than \$36.7M. The research we have funded has made remarkable advances in the treatment of childhood cancers. Our membership continues to grow, and best of all, we have been able to save young lives and give them the opportunity of a future.

To all of our outstanding members who have supported and contributed to this success, please accept our sincere thanks and appreciation. I wish everyone a very Merry Xmas and look forward to an exciting and prosperous New Year.

Geoffrey R Cattach AM

CHAIRMAN

October 2020




Chief Executive Officer's Report

I am pleased to report to the Members of the Children's Leukaemia & Cancer Research Foundation (Inc.) for the financial year 2019/2020.

Covid19

CORONAVIRUS

The 2019/2020 financial year started off like any other year but was thrown a curveball in 2020 with the emergence of Covid19. 2020 is the Foundation's 40th year funding child cancer research, and it was with much regret that celebrations for this milestone, along with other planned events, had to be cancelled or postponed.



Corporate Benefactors



In order to minimise the impact of the COVID-19 coronavirus outbreak on our local community, we had to make the decision to cancel many events that were planned to celebrate our 40th year. Although we rely on our events to help raise funds for childhood cancer research, the safety of our team, the families we collaborate with and the wider community is our number one priority. We also didn't want to ask for money from people in a time where many were losing their jobs and had such uncertain futures.

So, the team at CLCRF chose to pivot our 40Kin40days fundraising initiative, which was originally planned to be a fundraising campaign for the Foundation, and instead of asking for money we chose to use the opportunity to connect with 40 very generous businesses to provide gifts to those most deserving. Spreading kindness and bringing some joy to the lives of people who needed it most.

Each gift, valued from \$500 up to \$5000, and its associated business, was showcased on one of the 40 days of the campaign (from May 21 – June 30) across various social media channels and listed on the campaign website. We asked our supporters to nominate someone they know and share with us why they think they deserve it. We then read through all of the nominations and chose the nominee we believed to be most worthy of each gift.

The 40Kin40days campaign worked extremely well, garnering media attention and provided a great opportunity for CLCRF to connect with like-minded businesses, potentially sowing the seeds for future growth and connection with these new and existing business relationships. Furthermore, our goals will be to engage with these organisations and businesses like them, to become corporate members of the Foundation.

Beyond Bank

Community Reward

The Foundation enjoyed being chosen to participate, once more in the Beyond Bank Community Reward program. The program allows supporters (both individual and businesses) to contribute to not-for-profits and community organisations. In August 2019, the Foundation received a donation of \$3,236.06 from the results of this program. We believe there is a greater opportunity for community funding by utilising the program.

40Kin40days

Beyond Bank donated a \$500 Community Reward Account (CRA) for our 40Kin40days campaign.

Our thanks to Beyond Bank for their continued support. We are delighted to have forged a great corporate relationship with Beyond Bank.



The 2020 Toolmart Tradie Expo was cancelled due to Covid 19. During the June weekend, Foundation volunteers usually collected gold coin donations from patrons at the gate.

Toolmart generously supported the Foundation with other fundraising opportunities by providing a prize for our 40Kin\$40Days campaign – a 'Fat Bike' that was awarded to young Aiden Anderson, as well as donations from their vending machine sales and from donation tins at their various stores.



Corporate Benefactors

Justin Langer AM & Cricket Australia

Justin, in his 20th year as Patron for CLCRF, and the Australian Cricket Team Head Coach kindly donated an exclusive one-on-one meeting/session for 30 minutes. This was a great opportunity to ask him anything and all things cricket as well as discussing leadership.

Justin also donated a signed shirt by the 2019 Australian Men's Cricket Team, and a cricket bat gift approx value: \$2,500.



The Garden Gurus



The team at The Garden Gurus generously donated an ultimate Vegetable Garden Makeover, transforming a home space into an effective garden, filled with nourishing home grown produce. This gift had an approximate value of \$5000 and included a stunning design, soil improvement, garden bed construction, a variation of plantings, gardening books to help the winner learn more about their garden, and enough garden goodies to maintain healthy continual growth for over a year!



Springfree Trampoline



Springfree Trampoline jumped on board with a donation of a Jumbo Round Trampoline, the world's safest trampoline, which came complete with a full 10-year warranty. The incredible support from the team at Springfree trampoline has enabled us to build a national relationship with future supporters. Valued at \$2699.



GT Fabrication & Giovanetti Transport



GT Fabrication donated a 6x4 Trailer to help somebody get back to business or to replace an old one that wasn't cutting it anymore. Built here In WA this trailer was a very welcome gift to the winner.

The Trailer included half a tonne of firewood, thanks to Giovanetti Transport with a Total value of: \$1800 (trailer: \$1600, wood: \$200)



Absolute Edge Media



Absolute Edge Media, always supporting CLCRF anyway they can, donated an original photographic artwork by Creative Director Michele Seymour.

This original one-off piece is mounted in a hand crafted frame, with non-reflective glass. Approx value: \$2125



Grand Cinemas & Sony Pictures Australia



Grand Cinemas, who support the Foundation all throughout the year, donated two prizes for our campaign. Firstly 5 x Family passes (admit 4) to visit any of their cinema's locations, including drinks and popcorn. Approx value: \$500.

Secondly Grand Cinemas partnered with Sony Pictures Australia to offer a private Red-Carpet preview screening for 30 people of Sony Pictures Connected at a Grand Cinema location. Approx value: \$1000



Pullman Bunker Bay



Pullman Bunker Bay did not hesitate to donate a two-night stay in a luxurious two-bedroom villa, even though COVID-19 had deeply impacted their business during lockdown. This exclusive offer included a divine full buffet breakfast prepared by world class chefs, overlooking the tranquil waters of Bunker Bay. Approx value: \$1000



Galati & Sons



Galati & Sons is a family owned business that has supplied fantastic foods to Fremantle locals since 1958. It made sense to them to help those who need it most so they generously donated a \$200 fine foods hamper and a \$300 voucher for our 40kin40days initiative.



Autobahn



Autobahn has been a longtime supporter of CLCRF and kindly donated five \$200 vouchers to give away to 5 families who really need to get their cars serviced. Understanding that COVID-19 was really hitting hard from some WA families. Total gift value: \$1000.



Annie Sloan

Annie Sloan®

Annie Sloan, one of the world's leading authorities in paint, colour and style donated a Chalk Paint Gift. This was perfect for so many families who had been unable to travel during the year and were able to enjoy this gift to its fullest. Pack valued at \$521



Crust Pizza Fremantle



Crust Pizza in Fremantle generously donated \$500 worth of delicious food for our 40kin40days campaign. Knowing that this campaign was reaching those mostly in need there was a great feeling amongst the families who nominated for this gift.



Poppys Flowers Nedlands



Poppys Flowers were thrilled to be offer somebody a \$500 voucher to spend on florals in their Nedlands store as part of our 40kin40days campaign. The lucky recipient was able to use this gift for their wedding once people got back to having events.



No Probs Plumbing & Gas



It was very generous of No Probs Plumbing & Gas to donate a \$500 gift card for this first time gift with CLCRF. The lucky recipient was able to use it for any plumbing and gas fitting work, including materials and labour.



My Foodie Box



My Foodie Box offered a voucher of \$500 redeemable online for our 40kin40days campaign. A food box consisted of fresh ingredients along with easy-to-follow recipe cards for customers to cook at home restaurant-quality dinners in 30 minutes or less. Perfect for the stay at home part of 2020.



McLaurin Family

Special thanks to the McLaurin family for donating an authenticated AFL football, commemorating the 2019 Toyota AFL Premiership Season, personally signed by the 2019 Captain from each club. Includes a Certificate of Authenticity. Valued at over \$2000.



Skin Review



Skin Review in South Perth donated a gift basket plus individual Skin Review treatment vouchers for a specialized facial, 1hr body massage, deluxe pedicure, and Individualized eye treatment. Valued at \$1000. We look forward to seeing how this relationship of generosity continues



Selleys



Selleys were delighted to provide a selection of high-performance Dulux premium paints and Selleys paint preparation products to the value of \$1000. Renovating was one of the prime undertakings for 2020 and we know that this gift was truly appreciated.



Entertainment



Entertainment got on board the 40kin40days campaign when times were tough for all those who are in their books. By donating three Multi City Entertainment Memberships and two Single City Memberships to gift to our supporters we know they have shown tremendous understanding of this campaign. Approx value: \$500.



Mondo Doro



Mondo Doro is a West Australian owned and run smallgoods manufacturer and a wonderful supporter of CLCRF. They were thrilled to offer a deserving family one of their specialty hampers made up of \$400 worth of quality products from Mondo Doro and a \$100 Christmas voucher to be used for a Christmas Ham.



Kindy Dance Time



CLCRF Corporate Partner Kindy Dance Time, were honoured to offer a family, with a kindy aged child in 2021, a full scholarship to one of their 20 Kindy Dance Time locations. The team at KDT knew that isolating young children from their friends would be difficult and gave this gift hoping to bring the kids back together. Value up to \$700.



Leederville Cameras



When Leederville Cameras heard about the Circle of Kindness they were eager to participate and offered a deserving person or family a \$500 gift voucher to be used in store. CLCRF are keen to develop this relationship further and look forward to seeing how a mutual partnership might unfold in 2021.



Naked Wines & Roberto Fine Foods



Naked Wines and Roberto Fine Foods both very generously donated a great selection of gifts for our 40kin40days campaign. A full Naked Wines selection of \$200 crowd-pleasing wines along with a basket from Roberto Fine Foods, valued at \$300.



Westral



Westral kindly donated a \$750 Gift Voucher, redeemable against any of their extensive range of Home Improvement products including Blinds, Security Doors and Screens, Outdoor Blinds, Roller Shutters and Timber Shutters. We know the winner of this gift has already enjoyed receiving their blind and added to the order, thereby showing why It's beneficial for businesses to participate.



Dinner Twist



Fresh WA produce delivered to your door. With no food waste and locally sourced, seasonal ingredients, Dinner Twist is not only good for you but good for the planet as well. Dinner Twist generously donated four delicious boxes for 4 valued at \$636.



Camera Electronic



Camera Electronic understood what this campaign was trying to achieve and were extremely happy to be part of our circle of kindness and kindly donated a Mavic 2 Pro from DJI, valued at \$599.



Basile Imports



Basile Imports generously donated authentic delicacies from Europe's most highly regarded food artisans. They were proud to gift a deserving family a Gourmet Delights hamper with a bounty full of Cellar Chest premium wines. Valued at \$500.



Indian Ocean Hotel



The Indian Ocean Hotel happily donated the chance to enjoy a 2-night staycation in one of their superior rooms for a weekend. Not being able to travel far in 2020 meant it was a high value gift for a lot of the entrants. Valued at approximately \$475.



This Little Pig Went to Market & Onya



This Little Pig Went to Market offered four \$75 gift vouchers. Each \$75 voucher is the equivalent of two beautiful meals for two people, with the vouchers valid for 18 months.



Onya also donated a Bulk Food Set designed to provide a convenient way to reduce waste. The combined package was a very welcome gift for four lucky people.



Charlesworth Ballet



Charlesworth Ballet Institute donated a one-day pass for their 2020 Winter Holiday Program for two lucky children, valued at \$80 each. We hope to see them return In 2021 as their gift to our campaign was wonderful to include.





Benefactors

John & Janet Hughan **\$125,000**

CLCRF is once again very thankful to receive this very generous support from Mr & Mrs Hughan. The Hughan family have been supporting the Foundation since 1998.

Tate Family Foundation **\$29,000**

This was a welcome increase in funding this year. This gift represents the ninth year of the Tate Family Foundation's amazing support of childhood cancer research.



Stan Perron Charitable Foundation **\$10,000**

The Stan Perron Charitable Foundation has been a very loyal and generous supporter of our Foundation since 1996. We greatly appreciate our ongoing relationship with the Perron family and this Foundation.

Gifts in Wills / Endowment Funds

During the year under review, the Foundation received, in total, \$276,072 from the below-mentioned estates. CLCRF was unaware of these gifts until the benefactors had passed.

To these individuals and organisations, we extend our sincere thanks for their generous support of the Foundation. Many others have provided support and financial assistance during 2019/2020, their generosity is much appreciated.

Due to the Privacy Policy of FIA (Fundraising Institute of Australia), of which CLCRF is a member, we are not permitted to list donor names without permission. Therefore we will not be publishing the list of donations \$500+.

Hulyer, Marie J
Margaret Stevenson Endowment Fund
Ten Raa, Ruth R

Raffle Program / Western Charity Alliance (WCA)



Three raffles were completed during the year ending June 2020, in which WCA tickets were also sold. Revenue from these raffles totalled \$391,543 which, after expenditure, resulted in a surplus of \$89,132. Donations received via the raffles are included in the revenue figure.

The raffles continue to increase our profile in the community around Australia.

The Royal Life Saving Society WA (RLSSWA), through its call centres in Manjimup and Bridgetown, continues to undertake our telemarketing calls and the Hello Call Centre look after the administration of the raffle funds.

It should be noted that these raffles are on a cost-recovery basis and RLSSWA make NO profit from the services provided to the Foundation. We are extremely grateful to RLSSWA for their continued support of our cause; this relationship goes back well over 19 years.

Donation Appeal Campaigns

From each raffle campaign, the Foundation has been able to establish a database of donors in addition to raffle supporters. Tax and Xmas donation appeals were sent to this donor database in 2019/2020, as well as to a select number of donors from the Foundation database.

All four campaigns were successful and represent an effective complimentary fundraising program to the raffles. Net cash received from the campaigns was \$122,244 which was less than last year, mainly due to the economy and Covid19.





2019 South West Bike Trek

The Foundation's 17th South West Bike Trek kicked off at Mueller Park on Sunday 11th October 2019 and finished in Augusta on Saturday the 19th, covering approximately 600 kilometres.


This event would not be possible without the support of the many service clubs, shires, companies and individuals and in particular our Bike Trek Organiser – Eric Maddock and his wife Annette. During the 2019/2020 period \$32,748 was raised (under community activities) from the trek. Our thanks to PEACH (Personnel Employed at Alcoa Charity Help) for their support of this event.



2020 Quiz Night

The 2020 Keep the Flame Alive Quiz Night, initially scheduled for July had to be rescheduled – to November 2020, due to Covid19.





**Thank you
for helping us
spread**



kindness 40Kin40days.com.au

40kin40Days



A40Kin40Days campaign was created to raise \$40,000 in 40 days to recognise the 40th Anniversary of the Foundation.

As a result of Covid19 we pivoted this campaign to further develop the support of generous business/organisations. We encouraged donations of gifts over the value of \$500. These generous businesses can be viewed on pages 13-18 of this Annual Report. Supporters were asked to nominate people whom they thought deserved one of the items donated.

The new goal of this campaign was to create a more extensive database of supporters invested in CLCRF's goals, while building brand awareness through media attention. The response from our supporters and those businesses was truly amazing.



Community Activities

During the 2019/20 period, \$67,295 (excluding bike trek) was raised from community-based activities. This was a 29.5% reduction in funds raised from the previous year, which we would attribute to Covid19 restrictions.

This figure includes Entertainment Book sales, Kai's Big Gold Ball 2019, merchandise, event sales, annual donations from NIBA and service club support.

There have been many other events raising awareness and funds for CLCRF from the 2019 Family Night Out, 2019 Boar Swamp Campdraft, Kerrin's Hampson's Head Shave, annual Mandurah Over 55's Kayak Club, Rotary Club of Bunbury Golf Day, 2019 Nambung Country Music Muster, just to name a few. Our thanks to everyone for their passion and support in raising funds.



During the 2019/20 period \$67,295 (excluding bike trek) was raised from community based activities.

Foundation Update / Appeals



Two editions of the Foundation Update and two donation appeals were designed during the period under review.

Thank you to Michele Seymour from Absolute Edge Media for her expertise in this area of graphic design and support with the creation of stories.

We believe it is essential for the members who receive these newsletters to be kept up to date with what we are working towards and achieving each month.

Fundraising Platforms / PayPal Giving Fund

Support for the Foundation has continued to come from many people around the world. CLCRF's fundraising profile continues to be strong via the online fundraising entities such as Everyday Hero, Go Fundraise and My Cause.

Funds raised via these platforms totalled \$16,113 during 2019/20. Furthermore, we have been the beneficiary of donations from the PayPal Giving Fund totalling \$23,608.

PayPal
Giving Fund

fundraise with
facebook



Regular Giving

Several CLCRF supporters chose to move their donations to a regular giving basis during 2019/20.

Donations received from these gifts totalled \$14,845, again a reduction from last year, due to donors reviewing their support during Covid19. (under community activities).



Workplace Giving

This area of support decreased during 2019/20. Again, due to donors reviewing their support during COVID19.

CLCRF is registered with Good 2 Give Workplace Giving, which enables employees to make pre-tax donations to registered charities direct from their pay. CLCRF also received donations directly from several companies for their employees. A total of \$14,295 (under community activities) was received via this method of giving.

Membership

As at 13/10/20, the Foundation has 556 members of which 220 are financial for the 2019/20 period. Only financial members can attend the AGM and vote.

Members are critical to the ongoing success of our Foundation and we look forward to further developing reasons for people to become financial members of CLCRF. Please help support the Foundation in its research efforts by encouraging your friends, family and colleagues to become members.

CLCRF strives for effective strategies that align with our constitution and allow for fundraising efforts to grow. As a member, you can be confident that your financial support goes to the fundamental reason we exist, and that is to fund research.

As a member, you will be sent our annual newsletters which help to keep you informed about the research being funded and upcoming events. You will be invited to participate in our family-driven events each year and to share the journey with us as we grow. Each year you will have voting rights at the AGM, and we encourage all of our members to participate.



Schools / Colleges

During July to Dec 2019 support, totalling \$9,020, was received from schools/colleges around Australia.

Donations were received from Harvey PS (bike trek), West Leederville PS (pyjama day), Cassia PS (wear yellow for childhood cancer day), Kingston State School, Duncraig SHS (year 8 business studies students, St Joseph the Worker PS (donation from grade 5/6 class), Melville SHS, Waverley College (4km run), Lynwood SHS Soccer Academy (24 hour soccer match), Wattle Flat Public School, PLC, Aranmore Catholic College and the Primary Football Championships.


It is so wonderful to see children helping children in this way. Our thanks to all the students and their schools for choosing to support CLCRF.

Website

childcancerresearch.com.au

Absolute Edge Media continue to update our website regularly with details of events, stories, etc.

During the period under review, \$14,180 was donated via the website, this an increase of 182.7% from last year.



Social Media

Facebook

facebook.com/CLCRF

Currently CLCRF has 4,886 Facebook followers, compared to 4,335 last year. Facebook provides a powerful communication platform for our members & supporters. This also allows us to engage further with our supporters and reach a wider audience.

Content of our page is varied:

- information about events
- supporters who choose CLCRF to fundraise for
- donations received
- items relevant to childhood cancer
- CLCRF Flashbacks. Stories from our over 30-year history
- competitions
- social content

Twitter

We currently have 159 followers on Twitter. The Twitter account is mainly used when at events.

These social media platforms have proved to be of great benefit to the Foundation providing instantaneous communication with our supporters.

Instagram

[@CLCRF](https://www.instagram.com/CLCRF)

Instagram has been used to further expand CLCRF's online presence, providing an effective way for the Foundation to engage with supporters. We currently have a total of 620 followers on the popular platform.

As this is a photo-sharing platform, we have been able to create a more human-side to the Foundation by giving our followers a more visual look at what's happening at CLCRF. We have also utilised the story feature to share images and videos from our events in real-time.

The platform has been an excellent way to reach out to new supporters, especially through the platform's hashtag capabilities. When relevant, we use hashtags to ensure more people are able to find our content and learn more about the Foundation.

LinkedIn

CLCRF currently has 119 followers on LinkedIn which we utilise for more professional communications. We use the platform to share articles about childhood cancer research as well as our own stories and achievements. Through the platform, we are able to position ourselves as thought leaders in the industry and boost our reputation.

Since LinkedIn aggregates news that other professionals are sharing, we have been able to use the platform to stay up to date on what's happening in the industry and new developments in all types of cancer and leukaemia research.





Conclusion

According to the ACNC 2018 Australian Charities Report:

- charity revenue grew by over 6%, significantly more than the Australian economy in the same period (1.9%).
- Australian charities, overall, operated at a surplus, supported by substantial assets.
- revenue was up by \$9.3B, from \$146.1B in 2017 to \$155.4B in 2018.
- donations rose to \$10.5B, an increase of \$500M from the previous year.
- assets increased by \$18.7B to \$323B.
- the largest charities (0.4% of all charities) reported revenue of over \$100M.
- charities employed more than 1.3M people.
- charities spent \$81.1B on employee expenses, up 8% on the previous year's figure of \$74.8B.

There are approximately 56,000 registered charities in Australia. This figure is growing at almost 4% per year.

During the 2019/2020 period, the Foundation received donations from 645 new supporters and 1,346 established donors, with the average donation being \$229 (this excludes gifts in wills). This figure is slightly up from the previous year.

The first half of this year was devastating for many people and businesses. Whilst CLCRF did receive donations, many donors chose not to support the 2020 tax appeal. This is totally understandable with the situation happening in Australia. We hope that there will be a turnaround of this support within the next 12 to 18 months. It is expected that we will invest in other fundraising strategies to compensate for this loss and provide a robust plan for a sustainable future.

In February, Wendy and I attended the Fundraising Institute of Australia's international conference in Brisbane. Attendance at these conferences is essential for not-for-profit organisations to stay in touch with the industry and to network with peers. Thank you to the Committee of Management for their support of this professional development.

A big thank you to my staff for their tireless efforts, commitment and support of this wonderful organisation and its work. In my third year as CEO, I would like to thank the Committee of Management for their continued support. I would also like to thank Kim Williamson, whom I have known since 1984 and worked with for many years and Kimon Anderson for their commitment to CLCRF. It has been a pleasure working with you both.


I would like to take this opportunity to wish everyone a very Merry Christmas and a safe and peaceful 2021.

Andrea Alexander

CHIEF EXECUTIVE OFFICER

October 2020

Children's Leukaemia & Cancer Research 2019/2020





Overview of the Telethon Kids Cancer Centre

As Head of the Telethon Kids Cancer Centre (TKCC) I must say it has been one of the most challenging, but also the most successful years, in the history of the TKCC. Earlier in the year, the Telethon Kids Institute was significantly impacted by the COVID-19 pandemic. Virtually all laboratory work came to a halt before Easter and the Institute remained effectively closed for a month. After this time, laboratory work was slowly ramped up and returned to full capacity on June 22nd.

Fortunately, Perth has been successful in controlling the spread of the virus and is maintaining very strict borders. Consequently, we do not expect any further disruption in the medium term but will be prepared for any change in circumstances. I have spent many months in Melbourne supporting family under severe Stage 4 lockdowns but will be returning to Perth on October 26th.

As mentioned last year, we have been developing an Immunotherapy Program across the entire TKCC. This emerging therapeutic strategy has shown success in adult cancer and has great potential in paediatric cancer. CLCRF funds have been used in the past couple of years to help establish collaborations between the different TKCC groups in this exciting area of research. During the past 12 months we were successful in obtaining large grants to support this program from both the Australian Lions Childhood Cancer Research Foundation and the Stan Perron Charitable Foundation. This success was only possible because of the initial funding provided by CLCRF.

As you read through the different scientific reports, you will see the tremendous ongoing success of our researchers as evidenced by presentations and published papers. Our work is moving rapidly towards

the clinic in several different areas. One highlight was Dr Joost Lesterhuis, who was successful in obtaining a highly prestigious National Health and Medical Research Council Research Fellowship. CLCRF provided key funding to allow Joost to establish his new Sarcoma Translational Research Program at TKCC.

The word is out, TKCC is a fantastic destination for research. Our culture of success and making a difference for children with cancer has allowed us to recruit talented students and young staff. This has brought a new enthusiasm and energy to TKCC that is helping drive exciting discoveries.

Through the generous support of CLCRF, we have been able to recruit Emma Stone as our new TKCC Program Manager. Emma started in April and has already established herself as a critical member of the team. Her role involves high level administrative and financial support, and more importantly helping me develop and implement the strategic direction of TKCC.

CLCRF's extraordinary long-term financial commitment is central to this success. We thank you again for your support and trust. In return we commit to work even harder to improve the lives of children with cancer.

Your Sincerely,

Prof Terrance Johns

Funding: Oncogenic Signalling Laboratory, Telethon Kids Institute
Head Researcher: Professor Terrance Johns
Title: Development of a New and Effective Therapy Against Diffuse Intrinsic Pontine Glioma



The main aim of this project is to identify novel therapies that will be effective in High Grade Glioma (HGG), a serious type of brain cancer in adults and children. Targeted therapy is a cancer-specific treatment that uses drugs that target specific molecules involved in the growth of cancers. Unfortunately, this approach has failed for HGG to date, despite its success in other types of cancer.

Like normal brain cells, HGG cells are "plastic" which means they can rapidly adapt to different conditions in their environment. When exposed to a targeted therapy, HGG cells quickly adjust and become resistant to the drug. We hypothesised that this process of plasticity is driven by ion channels, which are pore-forming proteins that control the flow of small charged molecules (like sodium and potassium) in and out of the cell. These flows of ions can rapidly change the internal wiring of a cell. For this reason, ion channels have been associated with brain plasticity.

We hypothesised that using drugs that block the ion channels found in HGG would prevent this plasticity, making targeted therapies more effective.

Our studies in adult high-grade glioma (HGG) and have made significant progress towards identifying ion channels found in HGG.

Specifically, we have:

1. Used genetic databases to identify the ion channels found in HGG patient samples. There are over 300 ion channels in humans and only a small number were found in HGG.
2. Confirmed that the ion channels identified were actually present in patient samples and in our patient-derived HGG cell lines.
3. Proved that these ion channels are functional in HGG cells using a state-of-the-art technology called "patch clamping".
4. Used this information to identify ion channel drugs that might stop the growth of HGG cells.
5. Found a combination of a targeted therapy and ion channel drug that shows significant promise as a treatment for HGG.

Thus, we have made exciting progress in this entirely new field of research.

With the help of CLCRF funding, we are now using the experience and knowledge gained from our studies in adult HGG to study ion channels in diffuse intrinsic pontine glioma (DIPG), a lethal childhood form of HGG.

We have recently recruited Dr Anya Jones (a skilled

bioinformatician) who is currently looking for the presence of ion channels in DIPG patient samples using public genetic databases. Initial work suggests that many of the ion channels found in HGG are also seen in DIPG. Occasionally the genetic data does not always match what is found in genuine tumour samples from patients.

Therefore, through the ANZCHOG Biobanking Network, we have

obtained a number of DIPG patient samples, which will be used to determine if these ion channels are genuinely found in patients. Profs Chris Jones (The Institute of Cancer Research, UK) and Michelle Monje (Stanford University, USA), world leaders in DIPG, have provided us with additional DIPG cell lines to study the biology of ion channels and assess therapeutic strategies. Dr Abbie Francis joined our team on June 30th, 2020 and is working

right now with the DIPG patient samples and cell lines. With our new team members, we expect to make significant progress over the next year, hopefully finding better treatments for this horrendous disease.

Additional Funding Leveraged

- WA Child Research Fund (2020-2022, \$249,945)

Relevant Presentations

Conference Presentation: International DIPG Symposium 2019, Invited Talk



Funding: Creation of Appt of Program Manager for the Telethon Kids Cancer Centre

Manager: Emma Stone

Title: Telethon Kids Cancer Centre Program Manager



The generous support of CLCRF enabled the Telethon Kids Cancer Centre to appoint me as their Program Manager in April; a position that has been long-needed in the Centre. I work closely with the Head of the Centre to manage and support the operations and strategic goals of our large, multidisciplinary research team. My core goal is to enable our researchers to focus on their research to achieve our vision of defeating childhood cancer.

Since joining the Centre, I have established relationships with the Cancer Centre team members, the Professional Services teams of the Institute, and other core stakeholders, to drive and maximise support for our researchers. Initial areas of focus have been to provide high level administrative support, financial management, project management, governance, promotion of our research, and assistance with funding opportunities such as grant applications.

I maintain close working relationships with CLCRF and other stakeholders

to ensure that their needs and milestones are met in a productive and timely manner. I undertake these tasks in a coordinating role, with significant support from the Institute's Professional Services teams including People and Culture, Finance, Communications, Development, and Research Development.

Together with the Head of the Centre and Research Team Heads, I have worked closely to build on the Centre's vision and strategy. The first strategic focus has been driving our goal to be a Comprehensive Cancer Centre by enabling an increased integration with the clinicians at the Perth Children's Hospital.


This partnership is fundamental to the success of the Centre as we work hand-in-hand to conduct a dynamic translational paediatric cancer research pipeline, with the children battling cancer being at the forefront of our research. Another core strategic focus has been building on our underpinning research theme of Cancer Immunotherapy and

creating focused research synergies between teams.

Another focus is building internal relationships within the Centre and ensuring our students and early career researchers are engaged and supported. In the challenging sector of medical research, career development and mentoring are vital. A further core function is to work closely with our Community Reference Group, who all have lived experience as parents of children who have battled cancer. This key group informs our research, ensures it is directly relevant, and assists with our grant applications.

I look forward to continuing to grow and support the Centre and our ground-breaking research over the coming year.

Funding: Triennial Block Grant (2019 - 2021)
Researcher: Dr Rishi S Kotecha and Dr Laurence C Cheung
Title: Identifying Novel Translatable Therapeutics for Infant Acute Lymphoblastic Leukaemia



Leukaemia is a cancer of the blood and is the most common cancer in children. Leukaemia cells multiply uncontrollably, such that they crowd out healthy blood cells. Acute lymphoblastic leukaemia is the most frequently occurring type of childhood leukaemia. International research over the past sixty years has led to massively improved cure rates. Around 90% of children and adolescents with acute lymphoblastic leukaemia can expect to be cured of their disease.

In sharp contrast, newborns and babies who are less than 12 months of age at diagnosis face a dismal outlook, with an event-free survival rate of less than 40%. In an attempt to find better treatment for these infants, international study groups have conducted many therapeutic studies with more intensive therapy. Unfortunately, this led to a large number of toxic deaths and did not improve overall survival. We urgently require novel therapies. Understanding the biology of this disease holds the key.

To study the biology, we investigated genetic features of the leukaemia cells from babies, and performed genetic analyses using state-of-the-art next generation sequencing technology. We gained novel insight into genes that are involved, their contribution to disease progression and resistance to chemotherapeutic drugs.

We confirmed that a gene called KMT2A is not in its normal position on chromosome 11 where it is normally located, and chromosome 11 is instead broken at the site and fused to part of another chromosome. We know that such fusions are only present in the leukaemia cells and not in the patient's normal cells, and that this confers poor prognosis for the patient.

We used the leukaemia specimens from the patients to generate cell lines, so that the cells can be kept alive in the laboratory. These cell lines allow us to determine which drugs are effective in killing the leukaemia cells. We have generated a panel of eight cell lines and used

the same methods to analyse their genetic features, as was done for the leukaemia cells from the patients. This confirmed that the cultured cells showed the identical fusions of the KMT2A gene as present in the leukaemia cells from the patients.

We then screened the cell lines against more than 3,600 approved cancer drugs, which is the first comprehensive assessment of drug response in leukaemia cells from babies. The information obtained clearly showed that some of the currently used drugs are not very effective at killing the leukaemia cells in the test tube. However, some of the novel drugs were very effective, yet are not used in contemporary protocols to treat patients.

In order to determine whether these new drugs would be able to enhance the efficacy of currently used drugs, we conducted a large screening experiment. We tested each new drug in combination with the nine cytotoxic drugs that are currently used to treat babies with leukaemia. There were several drug

combinations that were shown to enhance the killing of the leukaemia cells. Several of these successful drug combinations were further tested in our preclinical model system. We could demonstrate that this therapeutic approach effectively reduced the leukaemia burden and improved survival in vivo – the drug combinations were more powerful than each drug alone.

Our studies have identified new drug combinations that could be of benefit for babies with leukaemia. Significant achievements to date include in

depth investigations of romidepsin and gemcitabine, which are two drugs not currently used to treat infants with acute lymphoblastic leukaemia. Preclinical efficacy has been independently demonstrated for each of these agents in our preclinical models as detailed in the respective publications below. Our results have been presented internationally and are currently being integrated into clinical trials for infants with acute lymphoblastic leukaemia, thus findings from our research will directly benefit patients

on a global scale. Through this work, Dr Kotecha has been selected by the Children's Oncology Group to lead the next international clinical trial for infants with acute lymphoblastic leukaemia.

These and other studies have generated a number of research publications and have allowed us to leverage additional funding to support the work. These details are provided below.


Additional Funding Leveraged

- The Kids' Cancer Project Grant (2019): Combinatorial Therapeutics in High-Risk Infant Acute Lymphoblastic Leukaemia (Kotecha RS, \$132,158)
- National Health and Medical Research Council Early Career Fellowship (2018-2021): Combinatorial Therapeutics in High-Risk Infant Acute Lymphoblastic Leukaemia (Kotecha RS, \$344,657)
- Tour de Cure Scott Canner Young Researcher Research Grant (2018-2019): Identifying Novel Translatable Treatments to Improve the Outcome for Infants with Acute Lymphoblastic Leukaemia (Kotecha RS, \$125,000)
- The Royal Australasian College of Physicians Research Establishment Grant (2018-2019): Combinatorial Therapeutics in High-Risk Infant Acute Lymphoblastic Leukaemia (Kotecha RS, \$180,000)

Relevant Publications

- Breese EH, Kotecha RS, Guest EM. Acute lymphoblastic leukemia in infants: A distinctive, high risk subtype of childhood ALL. In Litzow MR, Raetz EA, ed. *Acute Lymphoblastic Leukemia: Translational Science and Clinical Management for Children and Adults from the Bench to the Bedside*. Springer 2020 [Accepted Book Chapter].
- Wander P, Cheung LC, Pinhancos SS, Jones L, Kerstjens M, Arentsen-Peters STCJM, Singh S, Chua GA, Castro PG, Schneider P, Dolman MEM, Koopmans B, Molenaar JJ, Pieters R, Zwaan CM, Kotecha RS, Stam RW. Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia. *Leukemia* 2020 [Online ahead of print].
- Cheung LC, Cruickshank MN, Hughes AM, Singh S, Chua GA, Ford J, Ferrari E, Oommen J, Malinge S, Lock RB, Kees UR, Kotecha RS. Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. *Haematologica* 2019;104(7):e300-e303
- Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, Campbell M, Escherich G, Ferster A, Gardner RA, Kotecha RS, Lausen B, Li CK, Locatelli F, Attarbaschi A, Peters C, Rubnitz JE, Silverman LB, Stary J, Szczepanski T, Vora A, Schrappe M, Valsecchi MG. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study. *Journal of Clinical Oncology* 2019;37(25):2246-2256.
- Cruickshank MN, Ford J, Cheung LC, Heng J, Singh S, Wells J, Failes TW, Arndt GM, Smithers N, Prinjha RK, Anderson D, Carter KW, Gout AM, Lassmann T, O'Reilly J, Cole CH, Kotecha RS, Kees UR. Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin. *Leukemia* 2017;31(1):40-50.
- Kotecha RS, Kees UR, Cole CH, Gottardo NG. Rare childhood cancers - an increasing entity requiring the need for global consensus and collaboration. *Cancer Medicine* 2015;4(6): 819-824.
- Kotecha RS, Gottardo NG, Kees UR, Cole CH. The evolution of clinical trials for infant acute lymphoblastic leukemia. *Blood Cancer Journal* 2014;4:e200.
- Kotecha RS, Ford J, Beesley AH, Anderson D, Cole CH, Kees UR. Molecular characterization of identical, novel MLL-EPS15 translocation and individual genomic copy number alterations in monozygotic infant twins with acute lymphoblastic leukemia. *Haematologica* 2012;97(9):1447-1450.
- Kotecha RS, Murch A, Kees U, Cole CH. Pre-natal, clonal origin of t(1;11)(p32;q23) acute lymphoblastic leukemia in monozygotic twins. *Leukemia Research* 2012;36(1):46-50.

Funding: Triennial Block Grant (2019 - 2021)
Researcher: Dr Laurence C Cheung and Dr Rishi S Kotecha
Title: Novel Therapeutics for Children with Leukaemia: Understanding and Targeting the Bone Marrow Microenvironment



Acute lymphoblastic leukaemia or ALL is the most commonly occurring childhood cancer. Seventy years ago, a few clinicians pioneered the use of what we now call chemotherapy - drugs that are toxic and preferentially attack leukaemia cells. Tremendous international cooperation by clinicians and scientists identified drug combinations that can eliminate ALL cells and cure patients. Steady progress has pushed the cure rate for favourable risk leukaemia subgroups to 90%; however, despite such advances leukaemia remains the second most frequent cause of death from cancer in children.

The burden of disease, calculated in "person years of life lost" due to disease, is 69 years for children with leukaemia, whereas for adult cancer it ranges from 9 to 35 years. Patients with leukaemia are treated with up to ten different chemotherapeutic drugs. These regimens are also very toxic to normal cells of the patients, and lead to short and long-term sequelae. Children who survive leukaemia suffer from these side-effects throughout their lives. Sadly,

in some patients the disease comes back and the patients relapse. Most relapses of ALL occur in the bone marrow where the disease originates. At the time a patient is diagnosed, the bone marrow does not contain many normal cells, but instead is almost totally replaced by ALL cells.

The cause of relapse is often due to the fact that the chemotherapeutic drugs are no longer toxic to the leukaemia cells, as the cells have modified their genetic features and as a result have become resistant. Leukaemia cells also use another escape method which is triggered by a response in the bone marrow by the normal cells and bone cells that surround the leukaemia cells. These surrounding cells are commonly referred to as the microenvironment.

The response ultimately leads to protection of the leukaemia cells by the microenvironment. Our work has discovered that ALL cells have the capacity to influence their environment.

Destruction of the bone is commonly

seen in children with leukaemia, and many patients suffer from bone pain at diagnosis, yet little is known about the association of bone loss and the progression of leukaemia.

We have successfully developed a novel in vivo model that allows comprehensive investigation of the bone cells and surrounding normal cells in the bone marrow during leukaemia development. Importantly, this model faithfully replicates human disease and the clinical symptom of increased bone fragility and reduced bone mineral density in children with a diagnosis of ALL.

We first investigated development of the disease in our model system and monitored each population of the surrounding normal cells. We could clearly show that during the initial phases the leukaemia cells did not expand, however the environment was remodelled to facilitate the subsequent support of the cancerous growth. Notably, the normal production of blood cells and immune cells in

the bone marrow were affected during leukaemia development. The combined reactions of the surrounding cells then appear to trigger expansion of the leukaemia cells, and this happens very rapidly. Understanding this cascade of events opens up new avenues to interfere with the disease process and to design new therapeutic approaches. Our goal is to find inhibitors of these mechanisms to stop the development of leukaemia.

We further discovered that bone-eating cells were highly active during the development of leukaemia. We tested an inhibitor of bone-eating cells, zoledronic acid, which has

the capacity to reduce bone loss in patients with other conditions. We found that treatment reduced leukaemia progression and extended survival in our model. In addition, zoledronic acid improved treatment outcome when combined with currently used chemotherapeutic drugs. Unlike chemotherapeutic drugs, zoledronic acid is safe and well tolerated by children, and is already in clinical use in children for a wide variety of indications. Our findings suggest restoration of the normal microenvironment in the bone marrow to control cancer progression as a promising therapeutic avenue.

Currently, we are investigating the role of bone marrow immune cells, mesenchymal stem cells, fat cells and bone-forming cells during leukemia development with the aim to identify additional new therapeutic targets for children with leukaemia.

These and other studies have generated a number of research publications and have allowed us to leverage additional funding to support the work. These details are provided below.

Additional Funding Leveraged

- Cancer Australia Priority-driven Collaborative Cancer Research Scheme (PdCCRS) (2021-2022): New therapeutic strategies for children with high-risk leukaemia by dissecting and targeting the bone marrow microenvironment (Cheung LC, \$199,530)
- Tour de Cure Support Scholarship (2020). PhD Scholarship (Hughes A, Cheung LC, \$10,000).
- Tour de Cure Young Researcher Research Grant (2019-2020): New therapeutic opportunities by targeting the bone marrow microenvironment of high-risk childhood leukaemias (Cheung LC, \$98,020)
- Cancer Council WA (CCWA) Suzanne Cavanagh Early Career Investigator Grant (2018-2019): Unveiling the interaction between leukaemia cells and bone cells (Cheung LC, \$34,723)
- Perth Children's Hospital Foundation Project Grant (2018-2020): Exploiting the use of zoledronic acid to improve the outcome in childhood leukaemia (Cheung LC, Kotecha RS, Tickner J, \$78,554)
- Telethon-Perth Children's Hospital Research Fund (2017-2019): Zoledronic acid to improve outcome of children with high risk leukaemia (Cheung LC, Kotecha RS, Tickner J, Kees UR, \$242,470)

Relevant Publications

- Kotecha RS, Cheung LC. Targeting the bone marrow microenvironment: a novel therapeutic strategy for pre-B acute lymphoblastic leukemia. *Oncotarget* 2019;10(19):1756-1757.
- Cheung LC, Tickner J, Hughes AM, Skut P, Howlett M, Foley B, Oommen, J, Wells JE, He B, Singh S, Chua GA, Ford J, Mullighan CG, Kotecha RS,* Kees UR.* Dissecting the pre-B leukemia bone marrow microenvironment reveals new therapeutic opportunities. *Leukemia* 2018;32(11):2326-2338.
- Wells JE, Howlett M, Halse HM, Heng J, Ford J, Cheung LC, Samuels AL, Crook M, Charles AK, Cole CH, Kees UR. High expression of connective tissue growth factor accelerates dissemination of leukaemia. *Oncogene* 2016;35(35):4591-4600.
- Wells JE, Howlett M, Cheung LC, Kees UR, 2015. The role of CCN family genes in haematological malignancies. *Journal of Cell Communication and Signaling* 2015;9(3):267-278.
- Cheung LC, Strickland DH, Howlett M, Ford F, Charles AK, Lyons KM, Brigstock DR, Goldschmeding R, Cole CH, Alexander WS, Kees UR. Connective tissue growth factor is expressed in bone marrow stromal cells and promotes interleukin-7-dependent B lymphopoiesis. *Haematologica* 2014;99(7):1149-1156.

Funding: CLCRF – Ursula Kees fellow (2017 - 2021)
Researcher: Dr Sébastien Malinge
Title: To develop new tools to identify cancer cells resistant to current therapy and test a new drug therapy to destroy them



Acute Leukaemia is the most common type of childhood malignancy, accounting for 30% of all paediatric cancers worldwide. In Australia, it is estimated that more than 240 children aged 0-14 years will be diagnosed with leukaemia each year (data from the Australian Government - Cancer Australia).

Outcomes for paediatric leukaemia have significantly improved over the recent decades, with current 5-year overall survival approaching 85%. Nonetheless, despite this success, leukaemia remains the second cause of death by cancer in children. Many children continue to have a poor prognosis, suffering from relapse or treatment related toxicity, which can lead to increased mortality and necessitate longer hospital admissions and ongoing care. Current therapeutic approaches have now reached their maximum potential, highlighting the need for new, efficacious, more targeted, and less toxic treatments.

Gain of chromosome 21 is one of the most common genetic alterations

seen in childhood leukaemia, but little is known about its role in leukaemia development. Children with Down Syndrome (DS) that carry an extra chromosome 21 (trisomy 21), have a 10 to 20-fold increased risk of developing acute myeloid leukaemia (known as DS-AMKL) and B-cell leukaemia (DS-ALL). While there are very good outcomes for DS-AMKL (nearly 95% cure), DS children with B-cell leukaemia have inferior outcomes compared to other children with B-ALL (overall survival 74% vs 89%; event-free survival 64% vs 81%), 3-fold higher treatment-related mortality and a higher rate of relapse (26% vs 15%). Therefore, more specific therapy combinations with enhanced tumour-targeting capability are urgently needed to improve long-term outcomes for children with DS-ALL.

Our overarching goal is to develop novel targeted therapies based on the knowledge that we are continuously accumulating on the role of the gain of chromosome 21. Using DS-leukaemia as a disease model, we aim to identify new

actionable targets that will be beneficial for any other children with leukaemia characterised by gains of the chromosome 21, not only DS children with Down Syndrome.

To achieve this goal, we are building new experimental models to assess the therapeutic impact of targeting the mechanisms altered by gain of chromosome 21. Over the last few years, we reproduced the multi-step process of leukaemia development seen in Down Syndrome children and showed that trisomy 21 acts in cooperation with other genetic alterations to alter foetal and adult haematopoiesis, providing critical insights into leukaemia development and blood cancers in general. Indeed, this study showed that trisomy 21 cooperates with JAK3 mutations to progressively enhance the pool of T-cells in several organs as observed with an aggressive form of cutaneous T-cell lymphoma developed by non-DS patients.

Over the last year, we have shown that a high proportion of childhood B-cell leukaemia subtypes with

gain of chromosome 21 (including samples collected from biobanks in Western Australia) harbor N/KRAS activating mutations. Through the development of the first preclinical cohort of DS-ALL patient-derived xenografts, we tested the efficacy of RAS/MAPK inhibitors alone and in combination with standard of care therapies, and showed that the integration RAS/MAPK inhibitors into current treatment protocols may be a promising strategy to improve outcomes for Down Syndrome children and non-DS children with B cell leukaemia.

Using the same framework, we are testing the efficacy of several drugs that target gain of chromosome 21

in a preclinical setting. Moreover, we have recently implemented a multi-omic approach to identify the DS-ALL leukemic cells that are resistant to standard of care treatment. In the near future, this will enable us to discover novel actionable targets in the few cells that resist standard of care treatment, and from which relapse originates. This knowledge will facilitate the development of new targeted therapies such as immunotherapy.

Through our ongoing collaborations with clinicians and several Australian biobanks, our long-term goal is to continue to build a comprehensive repository of preclinical models in Western Australia. From these

models, we are developing B-ALL cell lines, which will serve as important tools for testing new therapeutic agents in test tubes, prior to being assessed in a preclinical setting with conventional chemotherapy.

This strategy will enable us to identify new drugs with strong efficacy, tested directly on human leukaemia samples. This will facilitate a rapid translation of our research into clinical trials, with the view of improving the outcomes of a significant number of children with leukaemia (Down Syndrome or not) in Western Australia and across the world.

Additional Funding Leveraged

- 2020-2021 BHP Blue Sky Award, Co-CIA Malinge, \$100,000
- 2020-2021 ALCCRF, CIA Malinge, \$10,000
- 2020 Cancer Research Trust, project call, Co-CIA Malinge, \$30,000
- 2020-2023 Cancer Council Western Australia (CCWA) Research Fellowship, \$480,000
- 2019-2021 Jérôme Lejeune Foundation, CIA Malinge, \$133,442
- 2019-2020 IMPACT Perpetual, CIA Malinge, \$8,500

Relevant Publications

- Malinge S. SNAIL trail in myeloid malignancies. *Blood*. 2020 Aug 20;136(8):920-921.
- Laurent AP, Kotecha R and Malinge S. Gains of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with down syndrome. *Leukemia*. 2020 May 20.
- Laurent AP, Siret A, Ignacimouttou C, Diop MB, Jenni S, Tsai YC, Ross-Weil D, Aid Z, Prade N, Plassard D, Pierron G, Daudigeos-Dubus E, Lecluse Y, Droin N, Bornhauser B, Cheung L, Crispino JD, Gaudry M, Bernard OA, Macintyre E, Barin Bonnigal C, Kotecha R, Goegerger B, Ballerini P, Bourquin JP, Delabesse E, Mercher T and Malinge S. Constitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell Leukemia. *Clinical Cancer Research*. 2020 Jul 1;26(13):3307-3318.
- Fagnan A, Bagger FO, Piqué-Borràs MR, Ignacimouttou C, Caulier A, Lopez C, Robert E, Uzan B, Gelsi-Boyer V, Aid Z, Thirant C, Moll U, Tauchmann S, Kurtovic-Kozaric A, Maciejewski JP, Dierks C, Spinelli O, Salmoiraghi S, Pabst T, Shimoda K, Deleuze V, Lapillonne H, Sweeney C, Mansat-De Mas V, Leite B, Kadri Z, Malinge S, de Botton S, Micol JB, Kile BT, Carmichael CL, Iacobucci I, Mullighan CG, Carroll MP, Valent P, Bernard OA, Delabesse E, Vyas P, Birnbaum D, Anguita E, Garcon L, Soler E, Schwaller J, Mercher T. Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. *Blood*. 2020 Apr 2.
- Lopez CK, Noguera E, Stavropoulou V, Robert E, Aid Z, Ballerini P, Bilhou-Nabera C, Lapillonne H, Boudia F, Thirant C, Fagnan A, Arcangeli ML, Kinston SJ, Diop M, Job B, Lecluse Y, Brunet E, Babin L, Villeval JL, Delabesse E, Peters AHFM, Vainchenker W, Gaudry M, Masetti R, Locatelli F, Malinge S, Nerlov C, Droin N, Lobry C, Godin I, Bernard OA, Göttgens B, Petit A, Pflumio F, Schwaller J, Mercher T. Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia. *Cancer Discovery*. 2019 Oct 29. [Epub ahead of print]
- Cheung LC, Cruikshank MN, Hughes AM, Singh S, Chua GA, Ford J, Ferrari E, Oommen J, Malinge S, Lock RB, Kees UR, Kotecha RS. Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. *Haematologica* 2019;104(7):e300-e303
- Volk A, Liang K, Suraneni P, Li X, Zhao J, Bulic M, Marshall S, Pulakanti K, Malinge S, Taub J, Ge Y, Rao S, Bartom E, Shilatifard A, Crispino JD. A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis. *Cancer Cell*. 2018 Nov 12;34(5):707-723.e7.
- Rivera-Munoz P, Laurent A, Siret S, Lopez CK, Ignacimouttou C, Cornejo MC, Rameau P, Bernard OA, Dessen P, Gilliland GD, Mercher T and Malinge S. Partial trisomy 21 contributes to T cell malignancies induced by JAK3 activating mutations in murine models. *Blood Advances* 2018 Jul 10;2(13):1616-1627.

Funding: CLCRF
Researcher: Dr Joost Lesterhuis
Title: A new treatment to prevent sarcoma relapse after surgery



Sarcoma is the third most frequent cancer in children and young people. Soft tissue sarcoma is a group of cancers derived from muscle, fat or connective tissues, characterised by local aggressive growth.

Current treatments of sarcoma can have severe side effects and large surgical procedures are often required in order to get complete resection of all cancer tissue. For sarcomas in limbs this not infrequently involves amputation.

In addition, children will be treated with chemotherapy and/or radiotherapy to prevent relapse. Despite these aggressive treatments, the cancer recurs in approximately one third of the cases in high-risk soft tissue sarcoma in children. In adults, these percentages are even higher, for example around 50% in retroperitoneal sarcoma, with chemotherapy and radiotherapy providing little benefit, if any.

Sarcoma is a particularly under-investigated cancer because it

is relatively rare in adults (1% of cancers), thus receiving little interest from pharmaceutical companies. In children, however, sarcoma is the third most common cancer, representing about 15% of all cancers. More research is urgently needed as sarcoma prognosis and treatments have not changed in the last 20 years.

Our aim is to develop a biodegradable material that slowly releases immunotherapy drugs, which can be applied in the wound bed after surgical resection of soft tissue sarcoma. These drugs will attract and activate immune cells that can search and destroy remaining cancer cells, thus preventing the cancer from recurring.

This is a unique approach that tackles a particular important problem in sarcoma; local recurrence after intensive surgery, despite aggressive treatments with sometimes severe long-term side effects. Our therapy provides hope for a treatment that is easy to use,

that does not require additional treatments (the drug is released locally while the child goes through normal daily activities and after several weeks the biocompatible material is completely degraded) and does not come with severe side effects.

The work in this project is the result of a unique collaboration between material scientists and cancer immunologists/oncologists. Our aim is to have a prototype ready within 1-2 years that is optimised in mouse models and that we can take forward into clinical trials to help dogs with sarcoma. Because we will then have evidence of safety and efficacy in two independent animal models (an FDA requirement), we hope we will be able to take the final leap into clinical trials in patients with sarcoma within several years' time. The results obtained in sarcoma may be translated to other cancers that often relapse after surgery, such as paediatric brain cancer and other solid tumours.

In the past year, we have made good progress. We have made several iterations of a prototype gel, improving it along the way. We now have a gel that has the right consistency, the right degradation speed (it is completely taken up by the body in the right time frame), has the right release kinetics of the immunotherapy (it releases the drug over the desired period of time) and it is efficacious in preventing sarcoma from recurring, even when as much as 25% of the tumour is left behind after surgery. In addition, we have found that the wound healing response is not negatively affected

by the gel, rather, it is actually enhanced.

In the year going forward, we aim to test our gel in multiple preclinical models, test its efficacy in combination with standard of care therapy (chemotherapy/immunotherapy) and incorporate a biomarker into the gel that will allow us to optimise the dose when going to human clinical trials. We will also test several other immunotherapies and incorporate these into the gel.

Lastly, we aim to start a veterinary clinical trial in dogs with soft tissue sarcoma in collaboration with

veterinary oncologist Dr Ken Wyatt from Perth Veterinary Oncology. This was planned for this year, but due to COVID-19 we had a slight delay.

In addition to existing team members, Dr Joost Lesterhuis, post-doc Dr Rachael Zemek and PhD students Francois Rwandamuriye, the Sarcoma Translational Research team at the Telethon Kids Cancer Centre was further expanded this year with the addition of post-doc Dr Ben Wylie and research assistant Ellise Roper.

Additional Funding Leveraged

- NHMRC Investigator Grant (\$1,562,250; 2021-2025) Dr Lesterhuis WJ (CIA)
- Cancer Australia/The Kids' Cancer Project "Intraoperative immunotherapy to prevent relapse in soft tissue sarcoma" (\$395,050; 2020-2022) Dr Lesterhuis WJ (CIA), Dr Iyer S, Dr Wyatt K. Grant ID 1184331
- Simon Lee Grant for paediatric research (\$450,000, 2020-2022) Dr Lesterhuis WJ (CIA)
- Australian Lions Childhood Cancer Research Foundation (\$1.05M; 2020-2023) "Paediatric Cancer Immunotherapy Program" Johns T, Lesterhuis WJ, Endersby R, Malinge S, Kotecha R, Gottardo N, Waithman J, Foley B.
- Abbie Basson Sarcoma Research Scholarship (\$30,000, 2019-2022) (Rwandamuriye B, Lesterhuis WJ)
- Abbie Basson Sarcoma Research Scholarship (\$30,000, 2020-2022) (Weston B, Lesterhuis WJ)

Relevant Publications

- Chin WL*, Zemek RM*, Fear V, Casey TH, Forbes C, Tilsed C, Boon L, Bosco A, Forrest AR, Millward MJ, Nowak AK, Lake RA, Lassmann T*, Lesterhuis WJ* (Shared authors). Dynamic IFN signaling underlies treatment response to immune checkpoint therapy in cancer. Submitted
- Zemek RM*, Fear F, Forbes C, De Jong E, Boon L, Casey T, Lassman T, Bosco A, Millward MJ, Nowak AK, Lake R, Lesterhuis WJ*. Bilateral murine tumour models for analysis of the cellular and molecular events associated with immune checkpoint blockade. *Nature Protocols* 2020 May;15(5):1628-1648. (*Corresponding authors)
- Rwandamuriye FX, Weston BJ, Lesterhuis WJ*, Zemek RM*. A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies. *Journal of Visualized Experiments* 2020 Jul 28;(161). doi: 10.3791/60882. (*Corresponding authors)
- Zemek RM, Chin W, Millward MJ, Nowak AK, Lake R, Lesterhuis WJ. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. *Frontiers Immunology* 2020 Feb 18;11:223. doi: 10.3389/fimmu.2020.00223.
- Zemek RM, De Jong E, Chin W, Fear F, Forbes C, Casey T, Hope D, Boon L, Forrest AR, O Muiri D, Millward MJ, Nowak AK, Lassman T, Bosco A, Lake R, Lesterhuis WJ. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. *Science Translational Medicine* 11 (501), eaav7816, 2019.
- Chin WL, Zemek RM, Lesterhuis WJ, Lassmann T. Functional genomics in cancer immunotherapy: computational approaches for biomarker and drug discovery. *Molecular Systems Design & Engineering*, 2019.

Financial Members as at 30 June 2020

A

Alexander Andrea & Gordon
Anderson Kimon & Sondra
Archibald Lesley
Astone Joe & Ivy
Aubin Paula

B

Bailey Philip
Ballantyne Patricia
Barbas Family
Barnett John
Barnett Margaret
Beer Campbell
Bennett Iris
Bentley Jan
Boogaard Annette & Austin Ken
Boulton Brian
Bowater Valma
Boyd James
Bradshaw John & Elizabeth
Brodie-Hall R & C
Brown Gerry & Thea
Bruce Justin
Bruce Philip *Life Member*
Bruce Christine
Bunn Tania & Loren
Burgess Donald
Burns Faith
Buttfield Jan

C

Calleja John
Cattach Brent
Cattach David & Jenny
Cattach AM Geoff *Life Member*
Cattach Stewart
Cattach Family
Causier David & Susan
Chandler Geoff
Chapman George & Lucy
Christian Bret
Clark Sue
Clifford Alistair
Couzens Kathleen
Covich John
Cox David
Cox Graham
Cox Mathew
Cruickshank Mark Dr
Curnuck Pia

D

Dalton Kylie
Davies Lesley
De Chiera PS & DM
De Nooyer Lein
Detiuk Michael & Georgina
Detiuk Tanya & Lloyd Kenda
Di Candilo G
Di Masi L & E
Dickson Stuart & Jennifer
Dodd EF
Draper Stephen & Karen
Ducey Gerry & Beryl
Dunning Vaughan

E

Elks Revele
Elliott Mary
Ellis Barry & Sue
English Skye
Escott Brenda

F

Falconer David & Leanne
Falconer OAM Peter *Life Member*
Fardon Andrew & Jackie
Fawcett Bob & Jan
Fels Brian
Fiorenza Antonio (Tony)
Flavel Don
Flis Family
Ford Peter & Jette
Foti Annita
Foti Charles
Frawley M & S
Frost Petra

G

Galati Cono & Trudy
Galati Sophie
Garner Family
Geddes David
Genovese/Fox Family
Germs Leanne
Giglia Maria
Gill Kevin
Ginbey Maria
Glass Thelma
Glenrowan Consultants P/L

Gobby Geoffrey
Godfrey Allan
Goetz Marilyn
Goode Des
Goulios Philip
Graham Rory & Christine
Graham Valerie
Grant Rosemary
Greenham Tim & Sue
Grosser Kerry

H

Haederle Mike & Judi
Hall Michael & Michelle
Hambley Rita
Hargrave Steve
Harper Peter *Life Member*
Harris Eileen
Harris Murray, Helen & Justin
Hart Roy & Linda
Heal Valda
Heenan Elizabeth
Heil Adrian
Hicks David & Pam
Hicks Sue
Hill Anne
Hill Christopher
Hill Charles & Joan
Hill Stan & Beryl
Hoffman Sandra
Horn Andrew & Therese
Howarth Family
Hutchings Les & Alice
Hutchings/English Brad & Cassandra

I

Italiano Harley
Italiano Robert & Minnie
Italiano Tyson
Italiano Zac

J

James Errol
Jarvis Stephen Dr
Jennings Brian
JG Brassingtons General Building
Services
Jupp Allan & Cheryl

K

Keane Brian
 Kearns Gary & Wendy
 Kees Ursula Prof *Life Member*
 Kelly Linda
 Kelly-Cook Danielle
 Kenda Renato & Annette
 Kennedy Nicole
 Kirkwood Kerrin
 Kitchen Mary
 Kounis Kaye

L

Lamb Phil
 Lane John, JP
 Langer Family
 Lazzarich Family
 Lee John
 Leeflang Carine
 Love Murray
 Lowry Georgia
 Lush Katelyn
 Lydon Larry & Isabell
 Lynch Andrew

M

Maddock Eric & Annette
 Mancuso Maruzza
 Marchant Family
 Marsell Marian
 Martin Sharon
 Matthews Daniel
 Maughan Chris
 McCallum Family
 McCorkill Ron Dr & Michelle
 McCormick Dorothy
 McCormick Steve & June
 McCreanor Madeline Dr
 McCusker Malcolm, AC, CVO, QC
 McDonald Ian
 McLaurin David & Diane
 Mendelson Joel
 Miller Rusty & Barbara
 Mills Nancy
 Milner Warren
 Milton John & Nui Drs
 Mincherton Glyn
 Mischin Michael, MLC
 Morrissy Jenny
 Murray Wendy

Myers John

N

Newton Tony
 Norton Daniel
 Nottle Pat
 Nowland David & Susanne

O

Oldham Neil & Shirley
 Oldham Tracey

P

Parker Michael & Cathrine
 Parkin Peggy
 Paulin Antony
 Peaker Shirley
 Powell Sandra
 Preece Christine

Q

Quinones Susanne

R

Reynolds Dwayne
 Riley Geoff & Mary
 Rodoreda Greg & Michelle
 Rose Steven & Helen
 Rotary Club of Harvey
 Rutherford David

S

Salamone Rebecca
 Schulze Dean
 Sealy Harold & Jeanette
 Senior Sue
 Sequeira Andre & Neicha
 Seymour Michele
 Seymour Patricia
 Silbert Lindsay & Suzanne
 Silsbury Robin
 Sim Paula
 Simons Eileen
 Sinclair Family
 Skinner James & Patricia
 Slatter Brian
 Somes Jane
 Spagnolo Family
 Sparks Amanda
 Stanley Fiona Prof, AC

Steel Peter & Christine
 Stone Stephen
 Storrs Julia
 Stuchbury Mark & Laura
 Sutton Peter & Glenda
 Swinbourn Matthew, MLC
 Syd Matthews & Co Pty Ltd

T

Tate Noelene
 Taylor JR Dr & MM
 Terms Alexandra
 Thomas Family
 Trewren Edith
 Turner Jim
 Turner Glen
 Turner Dr Keven & Fay

U

Udinga Alex & Jan

V

Van Der Lecq PSM & A
 Van Dijk H & C
 Villa Gillian
 Vogel Reto

W

Walker Richard
 Walton Judi
 Ward Joseph
 Warn Rosalie
 Warwicker Shirley
 Webb Brian & Maxena
 Wilborn Bernie
 Williamson Kim *Life Member*
 Williamson Jenny
 Wilson Lorna
 Wolfe Jeanette
 Wood Brendan & Margaret

ABN: 42 030 465 053

Financial Statements

Year Ended 30 June 2020



STATEMENT BY THE COMMITTEE OF MANAGEMENT

📍 Suite 3/100 Hay Street
Subiaco WA 6008

📮 PO Box 1118
West Perth WA 6872

PATRON - Justin Langer AM
ABN: 42 030 465 053

The Committee Members have determined that the Foundation is not a reporting entity, and that this special purpose financial report should be prepared in accordance with the accounting policies outlined in Note 1 to the financial report.


In the opinion of the Committee of Management, the accompanying financial reports:

1. (a) The financial statements and notes are in accordance with Part 5 of the Associations Incorporation Act 2015; and
(b) The accompanying Operating Statement gives a true and fair view of the operating excess of the Foundation for the financial year; and
(c) The accompanying Balance Sheet gives a true and fair view of the state of affairs of the Foundation as at the end of the financial year.
2. At the date of the statement there are reasonable grounds to believe that the Foundation will be able to pay its debts as and when they fall due.

This statement is made in accordance with a resolution of the Committee of Management and is signed by and on behalf of the Committee of Management by:



.....
Chief Executive Officer - Andrea Alexander



.....
Treasurer - Justin Bruce

Date: 05/11/2020

INDEPENDENT AUDIT REPORT

TO THE MEMBERS OF THE CHILDREN'S LEUKAEMIA & CANCER RESEARCH FOUNDATION (INC)

NICK DEL POPOLO
CHARTERED ACCOUNTANT
9 CARRINGTON STREET
NORTH PERTH, WA, 6006
Ph: 0419 922 776

5 November 2020

TO THE MEMBERS

THE CHILDREN'S LEUKAEMIA & CANCER RESEARCH FOUNDATION (INC)

We have audited the financial statements of Children's Leukaemia & Cancer Research Foundation (INC)(The Foundation) for the year ended 30 June 2020.

The Foundation's Management Committee are responsible for the preparation of the financial statements. We have conducted an independent audit of these financial statements in order to express an opinion on them to the members of the Foundation. The Management Committee's responsibility also includes such internal control as the Management Committee's determine necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

The audit has been conducted in accordance with Australian Auditing Standards to provide reasonable assurance as to whether the financial statements are free of material misstatement. Our procedures included examination, on a test basis, of evidence supporting the amounts and other disclosures in the financial statements, and the evaluation of accounting policies and significant accounting estimates. These procedures have been undertaken to form an opinion as to whether in all material respects the financial statements are presented fairly in accordance with Australian Accounting Standards so as to present a view of the Foundation which is consistent with our understanding of its financial position and the results of its operations.

The financial statements include fundraising receipts. It has not been practicable to determine whether pledged monies from external fundraising activities have been received and banked through the Foundation's accounts.

The Audit opinion expressed in this report has been formed on the above basis.

INDEPENDENCE

In conducting our audit, we have complied with the independence requirements of the Australian professional ethical pronouncements.

AUDIT OPINION


In our opinion, the financial statements present fairly the financial position of Children's Leukaemia & Cancer Research Foundation (INC) as at 30 June 2020 and the results of its operations for the year ended 30 June 2020 in accordance with applicable Accounting Standards to the extent described in Note 1.

In addition;

- a. The financial statements satisfy the requirements of Part 5 of the Associations Incorporation Act 2015;
- b. We have been given all information, explanations and assistance necessary for the conduct of the Audit;
- c. The Foundation has kept financial records sufficient to enable financial statements to be prepared and audited;
- d. The Foundation has kept other records as required by Part 5 of the Associations Incorporation Act 2015

EMPHASIS OF MATTER- BASIS OF ACCOUNTING

We draw attention to Note 1 to the financial report, which describes the basis of accounting. As a result, the financial report may not be suitable for another purpose. Our audit opinion is not modified in respect of this matter.



Nick Del Popolo
Chartered Accountant


Registered Company Auditor

AUDITOR'S INDEPENDENCE DECLARATION

TO THE COMMITTEE OF MANAGEMENT OF THE CHILDREN'S LEUKAEMIA & CANCER RESEARCH FOUNDATION (INC)

I declare that, to be best of my knowledge and belief, during the year ended 30 June 2020 there have been no contraventions of:
i. Any applicable code of professional conduct in relation to the audit

Name of firm: N DEL POPOLO
Name of partner: N DEL POPOLO
Date: 1st July 2020
Address: 9 CARRINGTON STREET
NORTH PERTH WA 6006



Nick Del Poppo
Chartered Accountant
Registered Company Auditor

Operating Statement 01/07/2019 - 30/06/2020

Revenue	2019/2020	2018/2019
Subscriptions	\$2,990	\$1,750
Donations & Promotions	\$208,069	\$204,868
Community Activities	\$157,119	\$131,053
Raffles & Direct Mail Campaigns	\$513,787	\$452,574
Schools & Associations	\$9,020	\$23,563
Commercial Support:		
Toolmart Australia	\$544	-
Triple Vend/Austway	\$250	\$1,850
United Fundraisers	\$1,779	\$1,061
VLT	\$274	\$1,048
Woolworths Australia	\$3,656	-
Grants & Gifts in Wills:		
Gifts in Wills	\$276,072	\$1,666,351
3BL (Brain Tumour Research Project)	\$315	\$2,080
JobKeeper Payments	\$36,000	-
ATO Cash Boost Payments	\$45,116	-
Interest Received	\$102,952	\$113,627
TOTAL	\$1,357,943	\$2,599,825
Expenditure	2019/2020	2018/2019
Admin, Staff & Other Costs	\$498,788	\$440,927
Depreciation	\$32,421	\$34,805
Raffles & Direct Mail Campaigns	\$304,411	\$198,887
Promotions & Events	\$110,588	\$112,876
Property Outgoings/Refurbishment	\$48,681	\$37,455
SUB-TOTAL	\$994,889	\$824,951
Appropriations	2019/2020	2018/2019
Research Funding/Grants July to June expenditure:		
PRO10111/20728 Block Grant	\$817,365	\$443,741
PRO12681 \$1Mio Grant of Excellence	-	\$8,111
PRO20221 Dr M Cruickshank - Therapeutic Targets for High-Risk Leukaemia	-	\$54,785
PRO20219 Molecular & Immuno-Therapy Targets for High-Risk Leukaemia - Dr M Cruickshank	-	\$98,355
PRO20328 Assoc Prof A Beesley - manuscript costs	-	\$1,700
Dr S Malinge - UR Kees Fellowship	\$294,446	\$327,624
PRO21183 Program Manager for TKI Cancer Centre	\$28,998	-
Unexpended from 2019/Adjustment	\$(140,809)	\$65,684
SUB-TOTAL - Appropriations	\$1,000,000	\$1,000,000
EXCESS/(DEFICIT) TRANSFER TO ACCUMULATED FUNDS	\$ (636,946)	\$ 774,874

The accompanying notes form part of the financial statements.

Balance Sheet - 30/06/2020

ACCUMULATED FUNDS	Notes	2019/2020	2018/2019
Balance as at 01/07/2019		\$7,247,048	\$6,472,174
Excess/(Deficit) from Operating Statement		\$(636,946)	\$774,874
TOTAL ACCUMULATED FUNDS		\$6,610,102	\$7,247,048

These Funds are represented by:

CURRENT ASSETS	2019/2020	2018/2019
Cash On Hand	\$100	\$100
Cash At Bank	\$276,640	\$409,983
Gaming Commission	\$31,995	\$31,145
Term Deposits	\$3,999,000	\$4,538,343
Total Cash Available	\$4,307,735	\$4,979,571

Pre-payment	\$500,000	\$500,000
Other Debtors	\$26,952	-
Trade Debtors	\$2,079	\$2,155
Shares at Cost	\$18,925	\$17,166
Share Options - At Cost	\$-	\$1
Change in Market Value	\$3,155	\$(12,526)
Total Current Assets	\$4,858,846	\$5,486,367

NON-CURRENT ASSETS	2019/2020	2018/2019	
Property - Land & Buildings			
Property 100 Hay Street Subiaco	2	\$886,630	\$886,630
Capital Improvements		\$121,626	\$121,626
Less: Accum Deprecation		\$(18,244)	
Provision for Diminution in Value		\$(198,256)	\$(198,256)
Provision for Depreciation		\$(86,850)	\$(64,684)
Computer Equipment at Cost		\$13,370	\$13,370
Less: Accum Deprecation		\$(12,686)	\$(20,675)
Collectables		\$2,199	\$2,199
Property - Vacant Land			
Property 26 Parnell Pde Bassendean	2	\$572,928	\$572,928
Property 28 Parnell Pde Bassendean	2	\$553,588	\$553,588
Total Non-Current Assets		\$1,834,305	\$1,866,727
TOTAL ASSETS		\$6,693,151	\$7,353,094

CURRENT LIABILITIES	2019/2020	2018/2019
Trade Creditors	\$(12,103)	\$(10,985)
Accrued/Sundry Creditors	-	-
Leave Liabilities	\$(67,230)	\$(91,824)
Provision for AL/LSL on-costs	\$(10,500)	\$(10,500)
Total Years Tax Liabilities	\$6,784	\$7,263
Total Liabilities	\$(83,049)	\$(106,046)
NET ASSETS	\$6,610,102	\$7,247,048

The accompanying notes form part of the financial statements.

Statement of Cash Flows - as at 30/06/2020

CASH FLOWS FROM OPERATING ACTIVITIES	Notes	2019/2020	2018/2019
Receipts from:			
Subscriptions		\$2,990	\$1,750
Donations and Promotions		\$208,069	\$204,868
Community Activities		\$157,119	\$131,053
Raffles and Direct Mail Campaigns		\$486,911	\$456,061
School and Associations		\$9,020	\$23,563
Commercial support		\$6,503	\$3,959
Grants and Gifts in Wills		\$357,503	\$1,668,431
Interest		\$102,302	\$112,369
Payments to clients, suppliers, employees and for research grants		\$(2,002,904)	\$(1,813,869)
Net cash provided by operating activities	3	\$(672,487)	\$788,187
CASH FLOWS FROM INVESTING ACTIVITIES		2019/2020	2018/2019
Investment in Term Deposits		\$(1,139,856)	\$(1,515,435)
Payments for Property, Plant & Equipment		-	\$(3,217)
Withdrawal of Term Deposits		\$1,679,000	\$810,000
Acquisition of PPE		-	-
Net cash used in investing activities		\$539,144	\$(708,652)
Net change in cash and cash equivalents		\$(133,343)	\$79,535
Cash and cash equivalents, beginning of year		\$410,083	\$330,548
Cash and cash equivalents, end of year		\$276,740	\$410,083

The accompanying notes form part of the financial statements.



NOTE 1 - Statement of Significant Accounting Policies

The significant accounting policies which have been adopted in the preparation of this financial report are:

Basis of Preparation

The Financial Report is a special purpose financial report, which has been prepared to meet the requirements of the Management Committee to provide information to the Children's Leukaemia & Cancer Research Foundation (Inc). The Foundation is not a reporting entity and is not obliged to adhere to the mandatory reporting requirements of the Australian Accounting Standards. Notwithstanding the special reporting status of the foundation, the Management Committee have, unless otherwise stated followed generally accepted accounting principles in accordance with Australian Accounting Standards. The accounts have been prepared on the basis of historical costs and do not take into account the changing value of money. The Accounting policies are consistent with those prepared in 2019.

Taxation and GST

Children's Leukaemia & Cancer Research Foundation (Inc) is an income tax exempt body.

The Net amount of Goods and Services Tax and GST recoverable from or payable to the Australian Taxation Office is included as a current asset or liability in the Balance Sheet.

Revenue, Expenses and Assets are recognised net of GST.

Employee Entitlements

The amounts expected to be paid to employees for their pro-rata entitlement to long service leave and annual leave are accrued annually at current pay rates.

NOTE 2 - Valuation of Non-Current Assets - Property

Hay Street, Subiaco was purchased on 02/09/2010 and is valued at market valuation. The Market Valuation is at 19/06/15 and is prepared by an independent licensed property valuer. 26 and 28 Parnell Parade, Bassendean, were transferred to the Foundation on 17/09/2013 by a deceased estate. They are valued at Committee of Management valuation based upon a real estate agents Appraisal and Report dated 18/09/2012 and a second real estate agents drive-by valuation dated 08/11/2013.

NOTE 3 - Operating Cash Flow

Reconciliation of cash flows from operating activities with current year operating excess.

CASH FLOWS FROM OPERATING ACTIVITIES	2019/2020	2018/2019
Net deficit for the year	\$(636,946)	\$774,874
Non-cash flows in operating deficit		
Depreciation	\$32,421	\$34,805
Diminution in share investments	-	\$(480)
Market value movements in share investment	\$(17,439)	-
Net changes in working capital:		
Change in trade and other receivables	\$(27,526)	\$2,709
Change in trade and other payables	\$1,597	\$(42,001)
Change in provisions	\$(24,594)	\$18,280
Net cash from operating activities	\$(672,487)	\$788,187



Children's Leukaemia & Cancer Research Foundation (Inc)

Suite 3 / 100 Hay Street
Subiaco WA 6008

PO Box 1118
West Perth WA 6872

+61 8 9363 7400
admin@childcancerresearch.com.au
www.childcancerresearch.com.au

facebook/clcrf
twitter.com/clcrf
instagram.com/clcrf
